These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 25642313)

  • 1. The biology behind PI3K inhibition in chronic lymphocytic leukaemia.
    Ortiz-Maldonado V; García-Morillo M; Delgado J
    Ther Adv Hematol; 2015 Feb; 6(1):25-36. PubMed ID: 25642313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
    Sanford DS; Wierda WG; Burger JA; Keating MJ; O'Brien SM
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):385-91. PubMed ID: 25817936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New oral small molecules in the treatment of chronic lymphocytic leukemia.
    Lamanna N
    Cancer; 2015 Jun; 121(12):1917-26. PubMed ID: 25690403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
    Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
    Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shifting paradigms in the treatment of chronic lymphocytic leukemia.
    Thompson PA; Shpall EJ; Keating MJ
    Future Oncol; 2015; 11(4):641-57. PubMed ID: 25686119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Sun C; Wiestner A
    Cancer Treat Res; 2015; 165():147-75. PubMed ID: 25655609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.
    Wiestner A
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):125-34. PubMed ID: 25696845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab.
    Smolej L
    Pharmgenomics Pers Med; 2015; 8():1-7. PubMed ID: 25691812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of adverse events associated with idelalisib treatment: expert panel opinion.
    Coutré SE; Barrientos JC; Brown JR; de Vos S; Furman RR; Keating MJ; Li D; O'Brien SM; Pagel JM; Poleski MH; Sharman JP; Yao NS; Zelenetz AD
    Leuk Lymphoma; 2015; 56(10):2779-86. PubMed ID: 25726955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obinutuzumab: A FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemia.
    Sachdeva M; Dhingra S
    Int J Appl Basic Med Res; 2015; 5(1):54-7. PubMed ID: 25664270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.
    Balatti V; Rizzotto L; Miller C; Palamarchuk A; Fadda P; Pandolfo R; Rassenti LZ; Hertlein E; Ruppert AS; Lozanski A; Lozanski G; Kipps TJ; Byrd JC; Croce CM; Pekarsky Y
    Proc Natl Acad Sci U S A; 2015 Feb; 112(7):2169-74. PubMed ID: 25646413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-malignant lymphoid cells arise from hematopoietic stem/progenitor cells in chronic lymphocytic leukemia.
    Kikushige Y; Miyamoto T
    Int J Hematol; 2015 Nov; 102(5):528-35. PubMed ID: 25644149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
    Wang Y; Zhang LL; Champlin RE; Wang ML
    Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs for diffuse large B-cell lymphoma.
    Mondello P; Younes A
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):439-51. PubMed ID: 25652253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia.
    Cerquozzi S; Owen C
    Biologics; 2015; 9():13-22. PubMed ID: 25733804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two distinct molecular subtypes of chronic lymphocytic leukemia give new insights on the pathogenesis of the disease and identify novel therapeutic targets.
    Cordoba R; Sanchez-Beato M; Herreros B; Domenech E; Garcia-Marco J; Garcia JF; Martinez-Lopez J; Rodriguez A; Garcia-Raso A; Llamas P; Piris MA
    Leuk Lymphoma; 2016; 57(1):134-42. PubMed ID: 25811675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
    Zelenetz AD; Gordon LI; Wierda WG; Abramson JS; Advani RH; Andreadis CB; Bartlett N; Byrd JC; Czuczman MS; Fayad LE; Fisher RI; Glenn MJ; Habermann TM; Harris NL; Hoppe RT; Horwitz SM; Kelsey CR; Kim YH; Krivacic S; LaCasce AS; Nademanee A; Porcu P; Press O; Rabinovitch R; Reddy N; Reid E; Saad AA; Sokol L; Swinnen LJ; Tsien C; Vose JM; Wilson L; Yahalom J; Zafar N; Dwyer M; Sundar H;
    J Natl Compr Canc Netw; 2015 Mar; 13(3):326-62. PubMed ID: 25736010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising therapies for the treatment of chronic lymphocytic leukemia.
    Morabito F; Recchia AG; Vigna E; De Stefano L; Bossio S; Morabito L; Pellicanò M; Palummo A; Storino F; Caruso N; Gentile M
    Expert Opin Investig Drugs; 2015 Jun; 24(6):795-807. PubMed ID: 25728009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53.
    Zent CS; Burack WR
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):119-24. PubMed ID: 25696844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia.
    Eagle GL; Zhuang J; Jenkins RE; Till KJ; Jithesh PV; Lin K; Johnson GG; Oates M; Park K; Kitteringham NR; Pettitt AR
    Mol Cell Proteomics; 2015 Apr; 14(4):933-45. PubMed ID: 25645933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.